

Johnson Matthey Inspiring science, enhancing life

Presentation of results for the year ended 31st March 2019

30th May 2019

Cautionary statement

This presentation contains forward looking statements that are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which Johnson Matthey operates.

It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated.



Strong performance whilst strengthening our platform for growth

Executing our strategy













Anna Manz Chief Financial Officer

JM


Delivered in line with our expectations

| Underlying results for year ended 31st March ¹ | 2019 £m | 2018 £m | % change | % change, constant rates |
|---|------------|------------|----------|--------------------------|
| Sales excluding precious metals (sales) | 4,214 | 3,846 | +10 | +10 |
| Operating profit | 566 | 525 | +8 | +8 |
| Finance charges | (43) | (39) | +12 | |
| Profit before tax | 523 | 486 | +8 | +7 |
| Taxation | (83) | (86) | -3 | |
| Profit after tax | 440 | 400 | +10 | |
| Earnings per share | 228.8p | 208.4p | +10 | |
| Ordinary dividend per share | 85.5p | 80.0p | +7 | |




^{1.} All figures are before loss on disposal of businesses, loss on significant legal proceedings, amortisation of acquired intangibles, major impairment and restructuring charges, significant tax rate changes, and where relevant, related tax effects.

Sales growth driven by Clean Air





Strong growth in underlying operating profit





Progressing on my three focus areas

Drive increasing business wide efficiency


Disciplined management of working capital

Rigorous and transparent resource allocation



Delivering now as we invest for the future

Operating profit up 8%





- 1. Includes procurement savings, restructuring and closure of Riverside that benefit the income statement.
- 2. Includes IT and procurement.

Group programmes


| £m | Annualised benefits | Achieved in the year | Cumulative achieved to date |
|-------------------|---------------------|----------------------|-----------------------------------|
| Procurement | 60 | 26 | 28 |
| Restructuring | 25 | 12 | 24 |
| Riverside closure | 20 | 15 | 15 |
| Total | 105 | 53¹ | 67 |

Good progress against our efficiency initiatives Three quarters of procurement initiatives will benefit the income statement


Some benefits being reinvested in the business to drive growth



1. Total savings of £53 million in the period includes £26 million procurement savings, of which £19 million benefited the income statement and £7m benefited capex.



Clean Air: Double digit sales growth in both light and heavy duty



2019/20 outlook: More modest growth in the year, weighted to H1

Operating profit up 13%


- Margin improved to 14.4%, up 0.2ppt
- Volume leverage

- Achieved 20ppt increase in light duty diesel market share in Europe
- Construction of new plants in China and Poland well underway; India early stages
- Maintained c.14% margin



Efficient Natural Resources: Sales growth and margin improvement

Sales up 4%



2019/20 outlook: operating profit growth ahead of sales

Operating profit up 15%


- Margin improved to 18.3%, up 1.8ppt
- Higher average pgm prices (+c.£16m)
- Net benefits from improved efficiencies
- Partly offset by investment in pgm refineries and weaker AGT performance

- Simplified product portfolio
- Commercialised newly developed technologies
- Restructuring substantially complete



Health: Sales growth with operating profit slightly down

Sales up 3%



2019/20 outlook: sales broadly stable and operating profit to grow double digit


Operating profit slightly down

- Decline in high margin products moving through life cycle
- Net costs due to manufacturing footprint optimisation

- Rationalised manufacturing footprint
- Invested and further progressed our API pipeline of generics and innovators



New Markets: Strong sales growth; eLNO commercialisation on track



Operating profit down 85%

- Higher costs due to eLNO investment
- Strong growth in lower margin battery systems sales
- Quality issues in Medical Device Components

- Significant progress in development and commercialisation of eLNO
- Fuel cells now profitable and investing further to sustain momentum



EPS growth slightly ahead of underlying operating profit growth

| Underlying results for year ended 31 st March ¹ | 2019 £m | 2018 £m | % change | % change, constant rates |
|---|------------|------------|----------|--------------------------|
| Sales excluding precious metals | 4,214 | 3,846 | +10 | +10 |
| Operating profit | 566 | 525 | +8 | +8 |
| Finance charges | (43) | (39) | +12 | |
| Profit before tax | 523 | 486 | +8 | +7 |
| Taxation | (83) | (86) | -3 | |
| Profit after tax | 440 | 400 | +10 | |
| Earnings per share | 228.8p | 208.4p | +10 | |
| Ordinary dividend per share | 85.5p | 80.0p | +7 | |



^{1.} All figures are before loss on disposal of businesses, loss on significant legal proceedings, amortisation of acquired intangibles, major impairment and restructuring charges, significant tax rate changes, and where relevant, related tax effects.

Reported results impacted by one-offs

| Year ended 31 st March | 2019 £m | 2018 £m | |
|---|------------|------------|--|
| Underlying operating profit | 566 | 525 | |
| Loss on disposal of businesses | (12) | (7) | |
| Loss on significant legal proceedings ¹ | (17) | (50) | |
| Amortisation of acquired intangibles | (14) | (19) | |
| Major impairment and restructuring charges ² | 8 | (90) | |
| Operating profit | 531 | 359 | |



^{1. £17}m in respect of a settlement with a customer on mutually acceptable terms with no admission of fault relating to failures in certain engine systems.

^{2.} The group is at an advanced stage of negotiations to sell the Riverside site for £7 million, net of costs, and an equivalent amount of the prior year impairment has been reversed during the year ended 31st March 2019

Free cash flow impacted by working capital

Free cash flow (£m)

| Year ended 31st March | 2019 | 2018 |
|--|-------|-------|
| Underlying operating profit | 566 | 525 |
| Depreciation and amortisation ¹ | 159 | 160 |
| Precious metal working capital outflow | (198) | (84) |
| Non precious metal working capital outflow | (26) | (64) |
| Net working capital outflow | (224) | (148) |
| Net interest paid | (47) | (42) |
| Tax paid | (95) | (77) |
| Capex spend | (300) | (209) |
| Other ² | (72) | (73) |
| Free cash flow | (13) | 136 |




^{2.} Includes movements in provisions and pension contributions in excess of service cost. 2017/18 also includes legal settlement and restructuring cash costs.




Precious metal working capital impacted by backlogs

Precious metal working capital (£m)



- Precious metal working capital improved £81m since H1
- Progress on backlogs masked by higher average precious metal prices

Precious metal backlog ('000 Oz)




- Good progress on reduction of ounces of precious metals in backlogs
- Expect to return to a normalised level in 2020/21
- Average Palladium price up 20% in 2018/19



Improvement in average non precious metal working capital days

Average working capital days excluding precious metals, year ended 31st March



Average working capital days were 59, an improvement of 3 days

11 day improvement since 2016

Continue to drive improvement in working capital




Strong balance sheet, net debt to EBITDA 1.3 times¹

| | £m | £m |
|---------------------------------------|-------|-------|
| Net debt at the beginning of the year | | (679) |
| Free cash flow | (13) | |
| Dividends | (156) | |
| Movement in net debt before FX | | (169) |
| Net debt before FX | | (848) |
| FX | | (18) |
| Net debt at the end of the period | | (866) |



Return on invested capital



Return on invested capital

- ROIC is 16.4%, down 0.6ppt from the prior year
- Precious metal working capital increased due to backlogs and higher average pgm prices
- Investing for growth in near term
- Remain on track for 20% ROIC in medium term



Note: ROIC excludes net pension assets.

2019/20 outlook

Operating performance within medium term guidance of mid to high single digit growth

Improvement in average working capital days (excluding precious metals)

Capex up to £500 million






Robert MacLeod Chief Executive

JM

Creating a more agile and efficient business



Better positioned in a fast changing world



Clean Air: delivering on expectations

Growth drivers

Strategy

Priorities

Improving air quality

Tighter emissions legislation, especially Asia

Global technology leadership

Customised solutions to meet tighter legislation


Efficient manufacturing footprint

Maintaining technology leadership through R&D

Capturing growth from further legislation change


Completing and ramping up new capacity

Delivering a mid single digit CAGR sales growth with a broadly flat margin





Building for the future









Sustained growth in Clean Air

2017 to 2019

2019 to 2025



- Additional c.20 ppts share in Europe Light Duty diesel
- Tightening legislation in Europe

Growth driven by:

- Tightening legislation in Europe and Asia
 - Europe 6 LD up to 2x value
 - China 6 LD up to x2 value
 - China VI and Bharat 6 HD x3 value

Partly offset by:

Continued Europe diesel decline and BEV penetration

Confident in sustained growth over the medium term



Efficient Natural Resources: solid progress

Growth drivers

Priorities

Making the most efficient use of the world's natural resources

Targeted investment in higher growth segments

Strategy

Focus on efficiency


Extend our capabilities into new technologies

Investment in new technologies

Expand newly developed licensing technologies

Continued investment in pgm refineries

Delivering sales growth 1ppt above markets (excluding PGMS) and operating profit growth 1ppt above sales growth





Health: significant operational progress

Growth drivers

Increased healthcare costs

driving more

targeted and potent APIs

Enhance performance of existing business

Strategy

Expand new product pipeline and portfolio

Build capabilities to better support customers

Priorities

Leverage our optimised manufacturing footprint

Generic pipeline to deliver c.£100m additional operating profit by 2025

Enhance our capabilities

Delivering break out growth





Battery Materials: significant progress

Growth drivers

Strategy

Priorities

Improving air quality

Increased BEV penetration requiring new technologies

Technology leadership

Focus on ultra high energy density market


Successful scale up and commercialisation

Start construction of first commercial plant and determine scale up plan

Further progress on customer qualification

Invest in customer application centres

Delivering break out growth





Tailoring solutions for our customers

Adding value for our customers

- "JM is a **preferred** cathode material company to work with due to fast response, **willingness to customise** the product [and] investing in science"
- "We value JM's scientific approach and are encouraged by JM's plans to continue to invest in application testing capabilities"
- Results from testing for a leading OEM show best in class performance for the majority of attributes tested, with top quartile for all attributes¹

Customer application centre

- Three best in class application centres
- Global focus two in the UK and one in Japan with a plan for further expansion
- Range of facilities from laboratories to demonstration cell manufacturing capability
- Key to delivering the tailored solutions our customers are asking for



Confident in our future

Another good year; delivered in line with expectations

Fundamentally changing the organisation as we execute our strategy

Strengthening our platform for growth

Exciting future prospects

Mid to high single digit EPS CAGR

Expanding ROIC to 20%

Progressive dividend






Appendix

JM

Light duty emissions control legislation roadmap






Global growth in vehicle production

Light duty vehicle production outlook (million)

Calendar years





Heavy duty diesel emissions control legislation roadmap



Europe

North America

North America (CARB)

Japan

South Korea

Brazil


Russia

India (Main Cities)

India (Nationwide)

China (Beijing & big cities)

China (Nationwide)



Non-road

Europe

North America

Japan

South Korea

Brazil

China


India





Heavy duty diesel vehicle production (regulated engines)

Heavy duty diesel vehicle (regulated engines) production outlook (thousands)
Calendar years





Health: Generic pipeline on track to deliver an additional c.£100m operating profit per year by 2025








- 1. Size of bubbles proportional to number of products.
- 2. Current pipeline as at April 2019.

eLNO has superior performance

\$ per kWh per cycle to end of useful life1

(chart to scale, indexed with eLNO = 100)



Step change in energy density from current materials

Lower cobalt content than current materials

Lower \$ per kWh per cycle than current and future materials¹



1. Cost per kWh to 80% retention. Results based on third party testing performed by QinetiQ, 2018. Electrochemical data from QinetiQ benchmark testing, cost data from JM. Electrochemical data extrapolated to 30Ah cell level.

eLNO: Commercialisation on track

| Stage | Validation | A sample | B sample | C sample | Battery cell in productio | production |
|--------------------|---------------|----------------------|--|------------------------------|---------------------------------|--|
| Summary | Early testing | Basic performance | Extended performance: basic plus safety, life performance | Full-scale functionality | | |
| Volume Required | kgs | < 10t | c.200t | c.300t | | |
| JM Supply | kgs | Pilot plant | Demo plant | Commercial plant | | |
| Timing | | c.12-18 months | c.12 months | c.12 months | | |
| Calendar year | | 2019 | 2020 | 2021 | | |
| | Today | | | Start of co productin 202 | ction | Supplying platforms in production in 2022/23 |

